loader
Please Wait
Applying Filters...

Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Selonsertib, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Selonsertib

    APIs // Active Pharmaceutical Ingredients

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    2D Structure
    1. Also known as: 1448428-04-3, Gs-4997, Selonsertib [inn], 5-(4-cyclopropyl-1h-imidazol-1-yl)-2-fluoro-n-(6-(4-isopropyl-4h-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide, Selonsertib(gs-4997), 5-(4-cyclopropylimidazol-1-yl)-2-fluoro-4-methyl-n-[6-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridin-2-yl]benzamide
    Molecular Formula
    C24H24FN7O
    Molecular Weight
    445.5  g/mol
    InChI Key
    YIDDLAAKOYYGJG-UHFFFAOYSA-N
    FDA UNII
    NS3988A2TC
    Selonsertib is an orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities. Upon oral administration, selonsertib targets and binds to the catalytic kinase domain of ASK1 in an ATP-competitive manner, thereby preventing its phosphorylation and activation. This prevents the phosphorylation of downstream kinases, such as c-Jun N-terminal kinases (JNKs) and p38 mitogen-activated protein kinase (p38 MAPK). By preventing the activation of ASK1-dependent signal transduction pathways, GS-4997 prevents the production of inflammatory cytokines, down-regulates the expression of genes involved in fibrosis, suppresses excessive apoptosis and inhibits cellular proliferation. ASK1, also called mitogen-activated protein kinase kinase kinase 5 (MAP3K5), is activated in response to oxidative and endoplasmic reticulum (ER) stress, calcium influx and infection. It plays a key role in the development of certain cardiovascular and neurodegenerative diseases, diabetes, as well as certain types of cancer.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    5-(4-cyclopropylimidazol-1-yl)-2-fluoro-4-methyl-N-[6-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridin-2-yl]benzamide
    2.1.2 InChI
    InChI=1S/C24H24FN7O/c1-14(2)32-13-27-30-23(32)19-5-4-6-22(28-19)29-24(33)17-10-21(15(3)9-18(17)25)31-11-20(26-12-31)16-7-8-16/h4-6,9-14,16H,7-8H2,1-3H3,(H,28,29,33)
    2.1.3 InChI Key
    YIDDLAAKOYYGJG-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=CC(=C(C=C1N2C=C(N=C2)C3CC3)C(=O)NC4=CC=CC(=N4)C5=NN=CN5C(C)C)F
    2.2 Other Identifiers
    2.2.1 UNII
    NS3988A2TC
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 5-(4-cyclopropyl-1h-imidazol-1-yl)-2-fluoro-n-(6-(4-isopropyl-4h-1,2,4-triazol-3-yl)-2-pyridinyl)-4-methylbenzamide

    2. Benzamide, 5-(4-cyclopropyl-1h-imidazol-1-yl)-2-fluoro-4-methyl-n-(6-(4-(1-methylethyl)-4h-1,2,4-triazol-3-yl)-2-pyridinyl)-

    2.3.2 Depositor-Supplied Synonyms

    1. 1448428-04-3

    2. Gs-4997

    3. Selonsertib [inn]

    4. 5-(4-cyclopropyl-1h-imidazol-1-yl)-2-fluoro-n-(6-(4-isopropyl-4h-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide

    5. Selonsertib(gs-4997)

    6. 5-(4-cyclopropylimidazol-1-yl)-2-fluoro-4-methyl-n-[6-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridin-2-yl]benzamide

    7. Gs 4997

    8. Ns3988a2tc

    9. 5-(4-cyclopropyl-1h-imidazol-1-yl)-2-fluoro-4-methyl-n-{6-[4-(propan-2-yl)-4h-1,2,4-triazol-3-yl]pyridin-2-yl}benzamide

    10. Gs-4997; Gs4997; Gs 4997; Selonsertib Free Base ;5-(4-cyclopropyl-1h-imidazol-1-yl)-2-fluoro-n-(6-(4-isopropyl-4h-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide

    11. Unii-ns3988a2tc

    12. 5-(4-cyclopropyl-1h-imidazol-1-yl)-2-fluoro-4-methyl-n-(6-(4-(propan-2-yl)-4h-1,2,4-triazol-3-yl)pyridin-2-yl)benzamide

    13. Njv

    14. Selonsertibgs-4997

    15. Selonsertib [jan]

    16. Gs-4997; Selonsertib

    17. Selonsertib [usan:inn]

    18. Selonsertib; Gs-4997

    19. Selonsertib [usan]

    20. Selonsertib (gs-4997)

    21. Selonsertib [who-dd]

    22. Selonsertib (jan/usan/inn)

    23. C24h24fn7o

    24. Gtpl9040

    25. Chembl3916717

    26. Schembl14672984

    27. Amy27913

    28. Bcp17814

    29. Ex-a1150

    30. Ex-a1618

    31. Bdbm50212258

    32. Gs4997

    33. Mfcd29920355

    34. Nsc797772

    35. S8292

    36. Akos027338646

    37. Zinc149387856

    38. Ccg-269184

    39. Cs-5328

    40. Db14916

    41. Nsc-797772

    42. Sb17466

    43. Ncgc00479176-02

    44. 5-(4-cyclopropyl-1h-imidazol-1-yl)-2-fluoro-n-(6-(4-isopropyl-4h-1,2,4-triazol-3-yl)-2-pyridinyl)-4-methylbenzamide

    45. Ac-31493

    46. As-35035

    47. Benzamide, 5-(4-cyclopropyl-1h-imidazol-1-yl)-2-fluoro-4-methyl-n-(6-(4-(1-methylethyl)-4h-1,2,4-triazol-3-yl)-2-pyridinyl)-

    48. Hy-18938

    49. Selonsertib Hcl Salt, Gs-4997 Hcl Salt

    50. D10988

    51. A857921

    52. Gs-4997; Gs4997; Gs 4997

    53. Q27088777

    54. 5-(4-cyclopropyl-1h-imidazol-1-yl)-2-fluoro-4-methyl-n-[6-[4-(1-methylethyl)-4h-1,2,4-triazol-3-yl]-2-pyridinyl]benzamide

    55. 5-(4-cyclopropyl-1h-imidazol-1-yl)-n-(6-(4-isopropyl-4h-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide

    56. Benzamide, 5-(4-cyclopropyl-1h-imidazol-1-yl)-2-fluoro-4-methyl-n-(6-(4-(1-methylethyl)-4h-1,2,4-triazol-3-yl)-2-pyridinyl)

    2.4 Create Date
    2013-03-21
    3 Chemical and Physical Properties
    Molecular Weight 445.5 g/mol
    Molecular Formula C24H24FN7O
    XLogP32.7
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count6
    Exact Mass445.20263658 g/mol
    Monoisotopic Mass445.20263658 g/mol
    Topological Polar Surface Area90.5 Ų
    Heavy Atom Count33
    Formal Charge0
    Complexity692
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of non-alcoholic steatohepatitis (NASH)

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Protein Kinase Inhibitors

    Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)

    Post Enquiry
    POST ENQUIRY